Using ADAPT® to find the answers
Led by Professor Leon Neethling, Admedus scientists and researchers are based at our bio-manufacturing facility in Perth, Western Australia.
The role of this division is to further develop regenerative tissue products, either in the cardiac space or other areas, all based on the ADAPT® tissue processing technology.
Admedus Tissue Engineering is also focussed on further development of the core technology and other potential regenerative medicine applications, such as the combination of cellular therapies and ADAPT® prepared regenerative tissue.
Using our patented ADAPT® Tissue Engineering Process, Admedus manufactures and distributes our cardiovascular scaffold CardioCel®, the first of a suite of implantable tissues that offer medical professionals a potential improvement over existing products that they currently use for a wide range of tissue repair and clinical applications.
Admedus technology has a number of advantages over current tissue treatment processes on the market, most notably the reduction of post-implantation calcification.
Our team of scientists are researching new ways we can use ADAPT® to develop other products which make a significant impact on the lives of patients and the medical professionals who treat them.
This includes further research into the ADAPT® technology, product development, preclinical & clinical studies, regulatory approvals and working with contract manufacturers to scale up production.
Key objectives include:
- Develop additional ADAPT® based products for additional cardiovascular applications, general vascular repairs (conduits & reconstruction) and hernia repair (implants)
- Progress further research into the use of CardioCel® to deliver stem cells or stem cell derived transformation/ growth factors to enhance tissue regeneration. Admedus Regen, in collaboration with CSIRO, showed that ADAPT® prepared CardioCel® is an effective delivery platform for delivering human stem cells
- Expand the ADAPT® Tissue Engineering Process as a platform technology to produce implantable tissue scaffolds for use in various soft tissue repair applications and for the production of replacement heart valves
Officially opened in August 2014, our state-of-the-art facility is the manufacturing centre for CardioCel® and our Tissue Engineering research and development hub.
At present, our bio-manufacturing facility is capable of performing the full spectrum of physical tensile testing, cross-link stability, enzymatic degradation assessment, application of the ADAPT® tissue engineering processing, microscopy analysis and essential biochemistry analysis.
The future focus of our research and development programme will be on product development.